Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

NCT00874614 is registered in ClinicalTrials.gov with Molecular Insight Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00874614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00874614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 4, 2009
Completion date
February 28, 2021
Enrollment
74 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

paraganglioma, pheochromocytoma